News | Radiopharmaceuticals and Tracers | October 02, 2015

Siemens’ PETNET Solutions Receives ANDA Approval for 18F Sodium Fluoride

Ninety-nine percent of U.S. population will have access to PET radiopharmaceutical for bone imaging

Siemens PETNET Solutions, 18F NaF, ANDA approval, PET radiopharmaceutical

Image courtesy of Siemens Healthcare

October 2, 2015 — Siemens’ PETNET Solutions has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) to manufacture and distribute sodium fluoride F 18 injection (18F NaF) across its entire national network of radiopharmacies. The approval for the positron emission tomography (PET) radiopharmaceutical will provide coverage to 99 percent of the U.S. population.

18F NaF is indicated for PET bone imaging to define areas of altered osteogenic activity in the body, including metastatic bone disease from cancer. Multiple clinical studies have demonstrated improved sensitivity and specificity of PET/computed tomography (PET/CT) imaging compared to single-photon emission computed tomography (SPECT)/planar bone imaging. Early identification of patients at higher risk for developing bone metastases enables practitioners to be proactive in their diagnosis and treatment.

PETNET Solutions is a wholly owned subsidiary of Siemens Healthcare.

For more information: www.siemens.com/healthcare

Related Content

PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
Novel PET Imaging Method Could Track and Guide Type 1 Diabetes Therapy
News | PET Imaging | August 03, 2018
Researchers have discovered a new nuclear medicine test that could improve care of patients with type 1 diabetes. The...
Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Overlay Init